Table 2.
Prevalence of reported symptoms of SARS-CoV-2 infection within the total seropositive sample, proportion of individuals with and without neutralizing antibody activity, and magnitude of surrogate neutralization activity by symptom for seropositive individuals.
| Total sample (%) (n = 790) | No neutralizing activity (%) (n = 504) | Neutralizing activity (%) (n = 286) | Median NAb (%) | 25th %ile | 75th %ile | |
|---|---|---|---|---|---|---|
| Headache | 41.27 | 35.52 | 51.40*** | 11.29 | 1.80 | 24.48 |
| Fatigue | 31.77 | 27.18 | 39.86*** | 11.09 | 2.23 | 29.75 |
| Sore throat | 28.48 | 28.37 | 28.67 | 9.26 | 1.74 | 18.37 |
| Cough | 27.97 | 21.83 | 38.81*** | 13.22 | 3.24 | 26.59 |
| Muscle or body aches | 27.59 | 21.03 | 39.16*** | 13.98 | 5.09 | 32.97 |
| Runny nose | 27.59 | 27.98 | 26.92 | 8.06 | 0.41 | 18.97 |
| Fever | 23.04 | 14.68 | 37.76*** | 18.37 | 6.33 | 39.12 |
| Diarrhea | 17.47 | 12.90 | 25.52*** | 13.98 | 2.65 | 36.6 |
| Shortness of breath | 13.29 | 8.33 | 22.03*** | 19.50 | 7.57 | 35.87 |
| Loss of sense of smell or taste | 13.80 | 5.36 | 28.67*** | 26.69 | 13.23 | 53.98 |
| Itchy eyes | 12.78 | 12.70 | 12.94 | 8.98 | 0.2 | 18.7 |
| No symptoms | 32.28 | 36.71 | 24.48*** | 4.91 | 0 | 13.95 |
N = 790.
Pearson chi-square test of independence: ***p < 0.001.